Paros Bio · Boston, Massachusetts LinkedIn

Home / Company

Company

A small Boston company built around one genetically defined form of Alzheimer’s disease.

Who we are

Transformative therapies for ADAD

Paros Bio is developing a gene replacement approach to treat Autosomal Dominant Alzheimer’s Disease caused by mutations in PSEN1.

The company is based at Tufts Launchpad I BioLabs in Boston, Massachusetts. Its own description on LinkedIn is a single line — “Transformative Therapies for Autosomal Dominant Alzheimer’s Disease” — and its site carries the same focus.

Everything published about the science is reproduced on the science page.

  • CompanyParos Bio
  • LocationTufts Launchpad I BioLabs, Boston, Massachusetts
  • FocusGene therapy for ADAD caused by PSEN1 mutations
  • PlatformAAV gene replacement
  • StagePreclinical
  • Headcount2, as listed on the company’s LinkedIn page
We anticipate that this novel approach will be a first in class treatment for ADAD, with the potential to slow or halt the progression of this devastating disease.
From the company’s own site

What is not published

The company’s site had pages for Company Overview, Our Team, In the News, Events and Careers. Only the home page and the Science page were ever captured, so no team names, news items or job listings survive.

Rather than invent a leadership page or a news feed, this rebuild leaves them out and says so. What the record contains.